The number of commercially insured patients who used indemnity plans in 1997 was drastically lower than it was in 1993, according to a new report from Mountain View, CA-based strategic research firm Frost & Sullivan.
The number of commercially insured patients who used indemnity plans in 1997 was drastically lower than it was in 1993, according to a new report from Mountain View, CA-based strategic research firm Frost & Sullivan.
According to the report, one out of two commercially insured individuals used a traditional indemnity plan in 1993. By 1997, that number had changed to almost one in ten.
The strength of managed care organizations, such as Aetna/US Healthcare, CIGNA Corp. and Kaiser was the primary factor behind the shift.
Although government and traditional indemnity insurers remain important sources of drug reimbursement, managed care organizations accounted for $24.9 billion of the $48.1 billion reimbursed last year.
"The most important issue facing the pharmaceutical manufacturers is ensuring that their drug is accepted by managed care organizations," said Marina Ulmishek, medical analyst at Frost & Sullivan. "It's imperative that competitors understand the process of how managed care organizations make drug-related decisions and what factors have the greatest influence over these decisions."
Also noted in the report were the climbing populations of uninsured, elderly and disabled patients.
Many of these individuals are currently covered by federal Medicare and Medicaid programs, but how those programs actually work - and how they reimburse for prescription products - may undergo a transformation as the number and needs of insured patients grow.
Ulmishek said: "As out-of-pocket payments continue to fall, companies must anticipate how different sources of reimbursement will influence their markets." PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.